Digest Network Come funziona
Network
/
Società
Si
Non verificato

Sinaptica Therapeutics, Inc.

Di cosa scriviamo

Attrezzature medico-sanitarieIndustriaMedicina - VarieSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati
18/06/2025
Biotecnologia
Igiene alimentare
Salute
Sanità
Attrezzature medico-sanitarie
Scienza
Medicina - Varie
Analisi di mercato
Industria
Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer’s
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/04/2025
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Psichiatria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Positive Data Published in Alzheimer’s Research & Therapy from 12-month Phase 2 Study in Alzheimer’s Using Personalized Neuromodulation Therapy; Trial Met All Primary and Key Secondary Endpoints
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/02/2025
Industria
Terza età
Sanità
Salute
Psichiatria
Attrezzature medico-sanitarie
Vetrine/Shopping
Medicina - Varie
Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/01/2025
Mercato del lavoro
Industria
Scienza
Attrezzature medico-sanitarie
Terza età
Medicina - Varie
Vetrine/Shopping
Salute
Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
31/10/2024
Eventi
Industria
Analisi di mercato
Scienza
Attrezzature medico-sanitarie
Terza età
Medicina - Varie
Salute
Vetrine/Shopping
Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/10/2024
Eventi
Industria
Scienza
Attrezzature medico-sanitarie
Terza età
Medicina - Varie
Salute
Vetrine/Shopping
Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of Precision Neuromodulation for Alzheimer’s Diseases in Oral Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/07/2024
Analisi di mercato
Industria
Biotecnologia
Salute
Terza età
Farmaceutica
Scienza
Attrezzature medico-sanitarie
Vetrine/Shopping
Medicina - Varie
Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients
Fonte
Sinaptica Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0